# Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

> **NCT02510950** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 1 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Astrocytoma, Grade IV

## Interventions

- **BIOLOGICAL:** Personalized peptide vaccine
- **DRUG:** Poly-ICLC
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02510950
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-03
- **Primary completion:** 2017-02-14
- **Final completion:** 2017-02-14
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02510950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02510950, "Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02510950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*